NIH RFA · NIDA · R01
RFA-DA-25-024: High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
The purpose of this Funding Opportunity Announcement (FOA) is to support high priority research at the intersection of HIV and substance use. This FOA invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD). Applications submitted under this FOA are required to have a detailed research plan, preliminary data, and a clear description of the nexus with substance use. This FOA is open to both individual researchers and research teams and includes all areas of research from basic science to clinical and implementation research. All studies must focus on…
- NOFO number
- RFA-DA-25-024
- Type
- RFA
- Activity code
- R01
- Primary institute
- NIDA · National Institute on Drug Abuse
- Clinical trials
- Optional
- Posted
- Aug 2, 2024
- Opens
- Jan 11, 2025
- Expires
- Mar 6, 2027
Projects funded under RFA-DA-25-024
NIH RePORTER lists 8 projects funded under RFA-DA-25-024 in FY2022–FY2026, with $6.7M in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
8
Distinct projects, FY2022–FY2026
New awards
8
Type 1 (new project) award records
NIH funding
$6.7M
Award dollars under RFA-DA-25-024, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 8 | 8 | $6.7M |
Institutions with the most funding
- Research Triangle Institute$1.8M · 2 projects
- University of South Carolina at Columbia$1.4M · 2 projects
- University of California, San Diego$1.2M · 1 project
- University of Pennsylvania$886K · 1 project
- Northwestern University$705K · 1 project
- Emory University$683K · 1 project
Funding institutes
- NIDA$6.7M · 8
Activity codes funded
- R018 records
Most recent new awards
- Effects of Smoking on Immune System Function at Single-Cell Resolution in People with HIV (opens NIH RePORTER)
Northwestern University · 1R01DA064599-01 · NIDA · Notice Aug 25, 2026
$705KR01
- Epigenetics of the neuroimmune axis in HIV and cannabis use (opens NIH RePORTER)
University of California, San Diego · 1R01DA066096-01 · NIDA · Notice Aug 24, 2026
$1.2MR01
- PrEP and OUD Treatment Extended Combination Therapy (PROTECT) (opens NIH RePORTER)
Research Triangle Institute · 1R01DA066095-01 · NIDA · Notice Jun 25, 2026
$1.2MR01
- Testing the Effectiveness of a Remote Intervention to Reduce Infection Risk in Rural Areas of the United States (opens NIH RePORTER)
University of Pennsylvania · 1R01DA064602-01A1 · NIDA · Notice Jun 25, 2026
$886KR01
- Cocaine and cannabinoids antagonize ART efficacy that promotes HIV infection and inflammatory responses at the maternal-fetal interface (opens NIH RePORTER)
Emory University · 1R01DA066140-01 · NIDA · Notice May 13, 2026
$683KR01
- Spatiotemporal Modeling to Improve HIV Prevention and Treatment for People who Use Drugs in the United States (opens NIH RePORTER)
Research Triangle Institute · 1R01DA066063-01 · NIDA · Notice Apr 27, 2026
$614KR01
What its predecessor RFA-DA-22-040 funded
RFA-DA-25-024 reissues RFA-DA-22-040. Its funding history is the best guide to who wins under this program: 19 projects and $52.0M in FY2022–FY2026.
Projects funded
19
Distinct projects, FY2022–FY2026
New awards
19
Type 1 (new project) award records
NIH funding
$52.0M
Award dollars under RFA-DA-22-040, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 4 | 4 | $3.0M |
| FY2023 | 10 | 6 | $8.0M |
| FY2024 | 18 | 9 | $14.2M |
| FY2025 | 19 | 0 | $13.5M |
| FY2026 | 18 | 0 | $13.3M |
Institutions with the most funding
- Yale University$10.1M · 3 projects
- University of Chicago$7.6M · 2 projects
- J. David Gladstone Institutes$6.3M · 1 project
- Drexel University$3.4M · 1 project
- Virginia Commonwealth University$3.4M · 1 project
- University of Alabama at Birmingham$3.3M · 1 project
- Ohio State University$2.9M · 1 project
- University of Miami School of Medicine$2.6M · 1 project
Funding institutes
- NIDA$52.0M · 69
Activity codes funded
- R0168 records
- R561 record
Most recent new awards
- Optimizing PrEP Care Delivery through Adaptive Intervention Strategies for Underserved Rural People who Inject Drugs (opens NIH RePORTER)
University of Kentucky · 1R01DA061996-01 · NIDA · Notice Sep 23, 2024
$667KR01
- Assessment of metformin for restoration of immune homeostasis in HIV+ and HIV- individuals with a history of injection drug use (opens NIH RePORTER)
University of Alabama at Birmingham · 1R01DA060692-01A1 · NIDA · Notice Sep 20, 2024
$1.1MR01
- Cell-type based epigenomic analysis to identify druggable genes for people living with HIV infection and using cannabis (opens NIH RePORTER)
Yale University · 1R01DA061926-01 · NIDA · Notice Sep 20, 2024
$1.0MR01
- A multidisciplinary approach to integrate HIV prevention services into clinical care settings for people with opioid use disorder (opens NIH RePORTER)
Miriam Hospital · 1R01DA059503-01A1 · NIDA · Notice Sep 19, 2024
$596KR01
- Estimating the direct and indirect effects of a status-neutral person-centric intervention on HIV transmission among PWID in India (opens NIH RePORTER)
Johns Hopkins University · 1R56DA059552-01 · NIDA · Notice Aug 7, 2024
$375KR56
- Next-Generation MEG Imaging for Quantifying Cortical-Subcortical Dynamics in the Context of HIV and Cannabis Use (opens NIH RePORTER)
Father Flanagan's Boys' Home · 1R01DA059542-01 · NIDA · Notice Jun 25, 2024
$640KR01
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under RFA-DA-25-024. Contact the program officer at the institute that fits your research before applying.
- NIDA · National Institute on Drug Abuse
- none
Related notices
Jan 28, 2026 · NOT-OD-26-029
NIH Removing AIDS Application Due Dates from NOFOs.
Mar 31, 2025 · NOT-OD-24-084
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy.
Notices of Special Interest (NOSIs)
NIH has attached 1 NOSI to RFA-DA-25-024; none are active now. A NOSI flags a topic an institute wants to fund through this NOFO.
Award terms
- Application types allowed
- NewRenewalResubmissionRevision The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budgets are not limited but need to reflect the actual needs of the proposed project.
- Project period
- The scope of the proposed project should determine the project period. The maximum project period is 5 years. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- NIDA intends to commit 3.0 M in FY 2025, 2026, and 2027 to fund 3-5 awards.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of RFA-DA-22-040.
- Companion NOFOs: RFA-DA-25-060.
Other open NOFOs for R01
- PAR-25-379Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)NIDA · next due Oct 21, 2026
- RFA-DA-26-034Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)NIDA · next due Nov 18, 2026
- RFA-DA-26-055Accelerating the Pace of Substance Use Research Using Existing Data (R01 Clinical Trial Not Allowed)NIDA · next due Dec 3, 2026
- RFA-DA-27-004BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (R01 Clinical Trial Not Allowed)NIDA · next due Oct 6, 2027
- PAR-25-371Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)NHGRI · next due Oct 20, 2026
- PAR-27-081Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)NIA · next due Feb 5, 2027
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.